ARTICLE | Clinical News
BAL3833: Phase I started
May 11, 2015 7:00 AM UTC
Basilea announced the start of an open-label, dose-escalation, U.K. Phase I trial to evaluate once-daily oral BAL3833 in adult patients. Basilea has exclusive, worldwide rights to develop and commerci...